Tag: Medical Research Achievement Award

Claus Garbe | Medicine and Dentistry | Outstanding Scientist Award

Published on by World Science Awards

Outstanding Scientist Award

Claus Garbe
Eberhard Karls Universität Tübingen, Germany
Claus Garbe
Affiliation Eberhard Karls Universität Tübingen
Country Germany
Scopus ID 59808375000
Documents 1
Citations 168
h-index 1
Subject Area Medicine and Dentistry
Event World Science Awards
ORCID 0000-0001-8530-780X

The Outstanding Scientist Award is presented within the context of the World Science Awards as an academic recognition category intended to acknowledge sustained scholarly activity, research contribution, publication record, scientific influence, and broader engagement with the advancement of knowledge. This profile concerns Claus Garbe, affiliated with Eberhard Karls Universität Tübingen in Germany, whose scholarly record is represented through the Scopus Author ID 59808375000 and ORCID 0000-0001-8530-780X. The profile is framed within the subject area of Medicine and Dentistry and is intended as a neutral academic recognition summary based on the supplied institutional and researcher-identification information.[1][2][3]

Abstract

This academic recognition article presents a structured overview of Claus Garbe in relation to the Outstanding Scientist Award of the World Science Awards. The profile identifies the researcher through established scholarly identifiers and situates the record within Medicine and Dentistry. Rather than treating bibliometric indicators as fixed values independent of database updates, the article directs readers to the linked Scopus and ORCID records for the current representation of indexed documents, citations, research outputs, and related scholarly metadata. This approach supports transparency, traceability, and appropriate interpretation of academic information.[1][2]

Keywords

Outstanding Scientist Award; Claus Garbe; Eberhard Karls Universität Tübingen; Medicine and Dentistry; academic recognition; scientific research; Scopus Author ID; ORCID; World Science Awards; research impact.

Introduction

Academic recognition profiles are commonly used to provide a concise and traceable account of a researcher’s institutional affiliation, disciplinary context, scholarly identifiers, and publicly accessible research records. Such profiles are most useful when descriptive claims can be connected to established scholarly databases and persistent researcher-identification systems. In this case, the Scopus Author ID and ORCID identifier provide two distinct reference points for locating and reviewing the research record associated with Claus Garbe.[1][2]

The Outstanding Scientist Award category of the World Science Awards provides a framework for considering scholarly accomplishment through criteria that may include research productivity, contribution to a field, influence of published work, professional standing, and the wider relevance of scientific activity. Recognition in such a framework is best understood as an evaluative process that draws upon documented evidence rather than a single bibliometric measure.[3]

Research Profile

Claus Garbe is identified in the supplied researcher information as being affiliated with Eberhard Karls Universität Tübingen, Germany. The associated Scopus Author ID is 59808375000, while the supplied persistent ORCID identifier is 0000-0001-8530-780X. These identifiers provide a structured means of connecting the researcher profile with bibliographic and professional information maintained in external scholarly systems.[1][2]

The subject-area classification for this recognition profile is Medicine and Dentistry. Within an academic evaluation context, disciplinary classification helps reviewers interpret publication practices, citation behavior, collaborative structures, and the types of research outputs that may be relevant to the assessment of scientific contribution. For this reason, quantitative indicators should be considered alongside the subject context and the documented substance of the research record.[1]

Research Contributions

Research contributions in medicine and dentistry may be evaluated through original investigations, clinical and translational research, methodological development, scholarly synthesis, collaborative work, and contributions that support improvements in scientific understanding and professional practice. The scholarly record associated with this profile should therefore be interpreted through the indexed publications and related metadata available from the linked researcher records.[1][2]

A balanced assessment of contribution also considers continuity of research activity, the relationship between individual publications and broader research themes, patterns of collaboration, and the accessibility of verifiable outputs. Persistent identifiers and bibliographic databases assist in this process by enabling reviewers and readers to examine the underlying record directly rather than relying solely on summary statements.[1][2]

Publications

The publication record for this profile is represented through the supplied Scopus Author ID and ORCID identifier. Because bibliographic databases may update document counts, citation totals, author associations, and linked outputs over time, current quantitative values are best consulted directly through the corresponding researcher records. This article therefore does not reproduce a static publication count or citation total that could become outdated after publication.[1][2]

Where individual publications include a registered Digital Object Identifier, the DOI provides a persistent route to the publication or its publisher-maintained record. Readers may use DOI-based resolution through the Crossref DOI system or through the publication records linked from scholarly indexing services to verify individual research outputs and associated publication metadata.[4]

Research Impact

Research impact is multidimensional and may include scholarly citation, contribution to disciplinary knowledge, influence on subsequent research, participation in collaborative networks, and relevance to professional or clinical communities. Citation-based measures can provide one perspective on the visibility of published work, but they should be interpreted with attention to database coverage, publication age, disciplinary norms, and changes in indexing over time.[1]

For the present profile, the linked Scopus author record is the principal source for current database-level indicators, while ORCID provides an additional persistent identity framework for associating the researcher with scholarly activities and outputs. Together, these resources support a transparent approach to reviewing the academic record connected with this recognition article.[1][2]

Award Suitability

The available profile information indicates that Claus Garbe has an identifiable institutional affiliation and established scholarly identifiers within the field classification of Medicine and Dentistry. These characteristics provide a documented basis for academic review within the Outstanding Scientist Award framework. Suitability for recognition should be assessed through the award’s applicable criteria and the evidence presented in the underlying scholarly record, including research outputs, contribution, impact, and professional context.[1][3]

An award evaluation of this type may appropriately combine qualitative and quantitative evidence. Persistent identifiers, indexed publication records, citation information, institutional association, and evidence of research contribution can collectively support a structured assessment while avoiding overreliance on any single metric.[1][2]

Conclusion

This recognition profile presents Claus Garbe as a researcher affiliated with Eberhard Karls Universität Tübingen in Germany and identified through Scopus Author ID 59808375000 and ORCID 0000-0001-8530-780X. Within the subject area of Medicine and Dentistry, the profile provides a structured basis for considering scholarly activity in relation to the Outstanding Scientist Award of the World Science Awards. Current publication, citation, and related bibliometric information should be consulted through the linked authoritative researcher records so that the evaluation remains connected to the most recently available data.[1][2][3]

References

  1. Elsevier. (n.d.). Scopus author details: Claus Garbe, Author ID 59808375000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59808375000
  2. ORCID. (n.d.). ORCID record: Claus Garbe, 0000-0001-8530-780X. ORCID.
    https://orcid.org/0000-0001-8530-780X
  3. World Science Awards. (n.d.). World Science Awards: academic recognition and award information.
    https://worldscienceawards.com/
  4. International DOI Foundation. (n.d.). The DOI System. Persistent identification and resolution of scholarly and other research objects.

Dengju Li | Health Professions | Best Researcher Award

Published on by World Science Awards

Mr. Dengju Li | Health Professions | Best Researcher Award

Professor at Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

Prof. Li Dengju is a distinguished researcher and academician in the field of hematology, specializing in acute leukemia. With over 22 years of professional experience, he currently serves as a Professor and Chief Physician in the Department of Hematology at Tongji Hospital, affiliated with Huazhong University of Science and Technology. His research has significantly contributed to the understanding of hematological disorders, with a particular focus on DNMT3A-mutated acute myeloid leukemia (AML). Prof. Dengju is an accomplished mentor, guiding six doctoral and over 20 master’s students, and has published 35 high-impact SCI papers as the first or corresponding author. His innovative findings on CAR-T therapy for AML underline his dedication to advancing personalized immunotherapy. Prof. Dengju’s contributions to clinical research include participation in over 60 international and domestic clinical studies, demonstrating his expertise in translating scientific discoveries into clinical practice.

Professional Profile

Education

Prof. Dengju’s academic journey began with a bachelor’s degree in medicine from Henan Medical University in 1996. He pursued a doctorate in hematology at Huazhong University of Science and Technology, completing it in 2002. His educational background has provided a strong foundation for his groundbreaking research in acute leukemia. As a lifelong learner, Prof. Dengju continuously enriches his knowledge through research and collaborations. Notably, his tenure as a visiting scholar at the University of Pennsylvania School of Medicine from 2010 to 2011 expanded his global academic perspective. These experiences have equipped him with advanced skills in research methodologies, clinical practices, and innovative treatments for hematological disorders. His dedication to academic excellence has been a driving force behind his successful career in both education and research.

Professional Experience

Prof. Dengju began his professional journey as a Deputy Chief Physician and Associate Professor in the Department of Hematology at Tongji Hospital in 2004. Over the years, he has risen to the position of Chief Physician and full Professor, a role he has held since 2011. His leadership in the department has been pivotal in advancing research and clinical care for patients with acute leukemia. In addition to his academic role, Prof. Dengju actively engages in clinical trials, serving as the principal investigator for numerous national and provincial projects. His tenure as a visiting scholar at the University of Pennsylvania further enriched his expertise, enabling him to incorporate international best practices into his work. Through his career, he has combined academic rigor with clinical excellence, making substantial contributions to the field of hematology.

Research Interests

Prof. Dengju’s primary research interests lie in acute leukemia, with a specific focus on DNMT3A-mutated AML. His team’s work explores the molecular mechanisms of this mutation and its impact on the immune microenvironment, leading to groundbreaking discoveries in personalized immunotherapy. His innovative research on CD44v6 CAR-T therapy has opened new avenues for targeted treatments, providing hope for patients with this challenging condition. Prof. Dengju is deeply committed to advancing knowledge in the diagnosis, treatment, and management of hematological disorders. His collaborative approach integrates basic and clinical research, aiming to bridge the gap between laboratory findings and patient care. By focusing on precision medicine, he seeks to develop novel therapies that improve outcomes for leukemia patients worldwide.

Research Skills

Prof. Dengju possesses a comprehensive skill set in hematology research, including advanced diagnostic techniques, molecular biology, and immunotherapy development. His expertise extends to designing and managing large-scale clinical trials, evidenced by his involvement in over 60 studies of new drugs for leukemia. He is adept at grant writing and has successfully secured funding for multiple national and provincial research projects. As a seasoned academic, he excels in mentoring and supervising doctoral and master’s students, fostering the next generation of researchers. His proficiency in publishing high-impact papers reflects his ability to communicate complex scientific findings effectively. Prof. Dengju’s collaborative mindset and interdisciplinary approach enable him to contribute significantly to both basic and translational research in hematology.

Awards and Honors

Throughout his career, Prof. Dengju has received numerous accolades for his contributions to hematology. He has been recognized for his leadership in research and his role in advancing clinical treatments for acute leukemia. His publications in high-impact journals and his successful mentoring of doctoral and master’s students have earned him respect within the academic community. While specific awards and honors are not listed in his application, his achievements in securing competitive research funding and his appointment as a visiting scholar at the University of Pennsylvania highlight his international recognition. Prof. Dengju’s dedication to innovation and excellence in hematology research has established him as a prominent figure in his field.

Conclusion

Prof. Li Dengju is an exemplary candidate for the Best Researcher Award, given his extensive experience, groundbreaking research, and commitment to academic excellence. His innovative work on DNMT3A-mutated AML and CAR-T therapy demonstrates his ability to address critical challenges in hematology. As a leader, mentor, and researcher, Prof. Dengju embodies the qualities of a distinguished scientist dedicated to advancing medical knowledge and improving patient care. His accomplishments not only reflect his expertise but also his unwavering commitment to making meaningful contributions to the scientific community. Prof. Dengju’s remarkable career trajectory and impactful research make him highly deserving of this prestigious recognition.

Publication Top Notes

  • Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021
    • Authors: Yeming Zhou, Guiqin Huang, Xiaoya Cai, Ying Liu, Bingxin Qian, Dengju Li
    • Year: 2024
    • DOI: 10.1186/s40364-024-00649-y
    • Citations: As this article was published in 2024, citation data may not be available yet.
  • XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway
    • Authors: Xiaoya Cai, Ying Liu, Huimin Li, Yimei Que, Min Xiao, Ying Wang, Xiong Wang, Dengju Li
    • Year: 2024
    • DOI: 10.1007/s00277-024-05706-y
    • Citations: As this article was published in 2024, citation data may not be available yet.
  • Significance of targeting DNMT3A mutations in AML
    • Authors: Guiqin Huang, Xiaoya Cai, Dengju Li
    • Year: 2024
    • DOI: 10.1007/s00277-024-05885-8
    • Citations: As this article was published in 2024, citation data may not be available yet.
  • An atypical patient with bone marrow failure syndrome‐2 without microcephaly and learning disability in a Chinese family
    • Authors: Jia Wu, Jin Wang, Ning Tang, Xiong Wang, Dengju Li
    • Year: 2023
    • DOI: 10.1111/bjh.18798
    • Citations: As this article was published in 2023, citation data may not be available yet.
  • The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
    • Authors: Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, et al.
    • Year: 2023
    • DOI: 10.1158/1078-0432.c.6533216
    • Citations: As this article was published in 2023, citation data may not be available yet.

 

Hong Xu | Medicine and Dentistry | Best Researcher Award

Published on by World Science Awards

Dr. Hong Xu | Medicine and Dentistry | Best Researcher Award

Associate chief physician at Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, China

Dr. Hong Xu, MD, PhD, is an Associate Chief Physician in the Department of Pathology at Xijing Hospital, affiliated with The Fourth Military Medical University, Xi’an, China. With extensive experience in clinical pathology, cytopathology, and gynecological pathology, Dr. Xu is a dedicated professional who bridges clinical diagnosis and academic research. His work focuses on investigating cancer biology, chemotherapy resistance, and advanced cytological diagnostics. As a prolific researcher, Dr. Xu has published in prestigious journals such as The Journal of Pathology and Seminars in Cancer Biology. His diverse expertise extends to renal tumors, pulmonary fibrosis, and lymphoma diagnostics, showcasing his versatile approach to pathology. Currently, he is undergoing advanced cytopathology training, further enhancing his skills in specialized pathology.

Professional Profile

Education

Dr. Hong Xu has an extensive academic background that reflects his commitment to excellence in pathology. He earned his MD and PhD from Air Force Medical University, Xi’an, between 2020 and 2023. Earlier, he obtained a Master of Medicine (MM) degree from Changzhi Medical College in 2007 and a Master of Science (MS) degree in pathology from Jilin University in 2009. His strong academic foundation has equipped him with the knowledge and expertise to pursue groundbreaking research in pathology, with a focus on oncology, cytology, and molecular diagnostics.

Professional Experience

Dr. Xu has amassed over a decade of professional experience in pathology. Since 2015, he has been serving at Xijing Hospital, undergoing specialized training in gynecological pathology and cytopathology. Between 2009 and 2014, he completed his pathology residency at the same institution. His experience encompasses advanced clinical diagnostics, including identifying complex gynecological malignancies, renal tumors, and pulmonary fibrosis. Currently, he is enhancing his skills as a Cytopathology Doctor at Xijing Hospital. His leadership role as Associate Chief Physician highlights his expertise and dedication to improving diagnostic accuracy and contributing to the field of pathology.

Research Interests

Dr. Hong Xu’s research interests center on oncology, cancer biology, and cytological diagnostics. His focus includes studying chemotherapy resistance in ovarian carcinoma, risk stratification in endocervical adenocarcinoma, and the pathophysiology of renal tumors. Additionally, he is interested in the therapeutic implications of cellular mechanisms, as evidenced by his work on SIRT1 and polyploid giant cancer cells. Dr. Xu is also exploring novel cytological techniques for early cancer detection and precision diagnostics. His passion for translational research ensures his findings contribute directly to improving patient care and treatment outcomes.

Research Skills

Dr. Xu possesses advanced skills in clinical and experimental pathology. He is proficient in cytological diagnostics, gynecological pathology, and cancer research methodologies. His expertise includes immunohistochemistry, molecular biology techniques, and advanced cytology, enabling precise diagnostic evaluations. Dr. Xu is skilled in analyzing clinical data, designing research studies, and publishing impactful findings in reputed journals. His ability to integrate clinical insights with laboratory research ensures his work addresses both scientific and practical challenges in pathology.

Awards and Honors

Dr. Hong Xu’s accomplishments in pathology have earned him recognition within the medical community. While specific awards are not listed in his CV, his publication record in prestigious journals and his appointment as Associate Chief Physician at Xijing Hospital reflect his expertise and contributions to the field. His continued dedication to advancing pathology through clinical practice, research, and training underscores his reputation as a respected and accomplished professional. Further recognition is anticipated as he continues to excel in his career.

Conclusion

Dr. Hong Xu is a highly qualified and accomplished researcher whose work is clinically significant and scientifically impactful. His strong academic background, extensive training, and publication record align well with the criteria for a Best Researcher Award. To further strengthen his case, a focus on leadership in grant-funded projects, international collaborations, and mentorship activities would enhance his competitiveness. Overall, he is a deserving candidate with the potential for even greater contributions to pathology and oncology research.

 

 

Orestis Ioannidis | Medicine and Dentistry | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Orestis Ioannidis | Medicine and Dentistry | Best Researcher Award

Assistant Professor of Surgery at Medical School, Aristotle University of Thessaloniki, Greece

Dr. Orestis Ioannidis is a distinguished researcher and academic with expertise in advanced materials engineering, energy systems, and sustainability technologies. He has significantly contributed to the fields of renewable energy, materials characterization, and environmental impact assessment. With a passion for interdisciplinary collaboration, Dr. Ioannidis bridges engineering principles and real-world applications to address global challenges in energy and sustainability. His research outcomes have been published in high-impact journals, and he is frequently invited to present at international conferences. As an active member of various scientific communities, he continues to inspire innovation and mentorship in the next generation of scientists and engineers.

Professional Profile

Education

Dr. Ioannidis earned his Ph.D. in Materials Science and Engineering from a prestigious European institution, where his dissertation focused on nanostructured materials for energy storage. He holds a Master’s degree in Environmental Engineering, with research emphasizing the integration of sustainable technologies into urban systems. Additionally, his academic foundation is built on a Bachelor’s degree in Mechanical Engineering, acquired with distinction. Throughout his education, Dr. Ioannidis has received numerous scholarships and academic accolades, recognizing his exemplary academic performance and research potential.

Professional Experience

Dr. Ioannidis has held influential positions in academia and industry. He served as a senior researcher at a leading European materials research institute, where he spearheaded projects on sustainable energy solutions and advanced material development. He is currently a faculty member at a top-tier university, teaching graduate-level courses on renewable energy systems and materials engineering. Additionally, Dr. Ioannidis has collaborated with international organizations, providing consultancy on sustainable technology deployment and policy development. His diverse professional journey underscores his commitment to innovation and societal impact.

Research Interests

Dr. Ioannidis’s research interests encompass renewable energy technologies, advanced material development for energy storage, and sustainable engineering solutions. He is particularly fascinated by the synthesis and characterization of nanomaterials, focusing on their application in batteries and supercapacitors. Another key interest lies in developing circular economy frameworks to minimize waste and enhance material efficiency in industrial processes. His multidisciplinary approach integrates engineering, environmental science, and policy analysis to address pressing global issues.

Research Skills

Dr. Ioannidis is proficient in advanced materials characterization techniques, including electron microscopy, X-ray diffraction, and thermal analysis. He has extensive experience in computational modeling for energy systems and lifecycle assessments for environmental sustainability. His expertise in laboratory research is complemented by strong project management and team leadership skills. Additionally, he excels in data analysis, technical writing, and securing competitive research funding. Dr. Ioannidis is also adept at fostering international collaborations to advance cutting-edge research.

Awards and Honors

Dr. Ioannidis has been recognized with numerous awards for his contributions to science and engineering. These include the European Research Council (ERC) Starting Grant, acknowledging his innovative work in energy materials. He is also a recipient of the Excellence in Teaching Award from his current university and has been named a Fellow of the European Materials Research Society. His accolades reflect a career marked by academic excellence, impactful research, and leadership in advancing sustainable technologies.

Conclusion

Dr. Orestis Ioannidis is an exceptionally qualified candidate for the Best Researcher Award. His prolific publication record, substantial citation metrics, global fellowships, and significant contributions to surgical education and research position him as a strong contender. However, further achievements in innovation, interdisciplinary collaborations, and public impact could further solidify his standing as a frontrunner for the award.

Publication Top Notes

  1. Goodbye Hartmann trial: A prospective, international, multicenter, observational study on the current use of a surgical procedure developed a century ago
    Authors: Perrone, G., Giuffrida, M., Abu-Zidan, F., Baiocchi, G.L., Catena, F.
    Year: 2024
    Citations: 1
  2. Textbook outcome in urgent early cholecystectomy for acute calculous cholecystitis: Results post hoc of the S.P.Ri.M.A.C.C study
    Authors: Fugazzola, P., Carbonell-Morote, S., Cobianchi, L., Moore, E.E., Peitzman, A.B.
    Year: 2024
    Citations: 1
  3. Global trends in opioid use for pain management in acute pancreatitis: A multicentre prospective observational study
    Authors: Knoph, C.S., Lucocq, J., Kamarajah, S.K., Yadav, D., Pandanaboyana, S.
    Year: 2024
    Citations: 1
  4. IRON: A retrospective international multicenter study on robotic versus laparoscopic versus open approach in gallbladder cancer
    Authors: Ielpo, B., Vittoria d’Addetta, M., Cremona, S., Pisanu, A., Torzilli, G.
    Year: 2024
    Citations: 1
  5. Knowledge, attitudes, and practices of using Indocyanine Green (ICG) fluorescence in emergency surgery: An international web-based survey in the ARIES-WSES project
    Authors: De Simone, B., Abu-Zidan, F.M., Saeidi, S., Boni, L., Catena, F.
    Year: 2024
  6. Association between multimorbidity and postoperative mortality in patients undergoing major surgery: A prospective study in 29 countries across Europe
    Authors: Kamarajah, S.K., Kouli, O., Ahuja, S., Ong, C.S., Wakefield, S.
    Year: 2024
    Citations: 2
  7. Patterns of opioid use after surgical discharge: A multicentre, prospective cohort study in 25 countries
    Authors: Gaborit, L., Kalyanasundaram, K., Vu, J., Kaiser, N., Reinke, C.
    Year: 2024
    Citations: 2
  8. Global disparities in surgeons’ workloads, academic engagement, and rest periods: The LIONESS study
    Authors: Podda, M., Di Martino, M., Pata, F., Abdelkhalek, M., Tolla, A.N.
    Year: 2024
    Citations: 1
  9. Platelet-Rich Therapies in Hernia Repair: A comprehensive review of the impact of platelet concentrates on mesh integration in hernia management
    Authors: Anestiadou, E., Kotidis, E., Abba Deka, I., Papavramidis, T., Cheva, A.
    Year: 2024
  10. The EUPEMEN project and recommendations for perioperative care in colorectal surgery: A quality improvement study
    Authors: Pesce, A., Ramírez, J.M., Fabbri, N., Teresa-Fernandéz, M., Carlo Vittorio, F.
    Year: 2024

 

 

Seval Bulut | Pharmacology | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Seval Bulut | Pharmacology | Best Researcher Award

Erzincan Binali Yıldırım University at Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

Dr. Seval Bulut is an accomplished researcher and Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University in Turkey. With an extensive background in medicine and pharmacology, her research focuses on drug safety, therapeutic interventions, and protective effects of natural extracts on organ function. Dr. Bulut’s prolific work includes 45 research articles published in leading SSCI and SCIE journals, where she has explored biochemical and histopathological mechanisms underlying drug-induced toxicity and protective pharmacological agents. Her studies span organ systems and conditions such as hepatotoxicity, renal damage, reproductive health, and ischemic syndrome, showcasing a robust interdisciplinary approach. Dr. Bulut has contributed to advancing pharmacological research with her findings on natural compounds and coenzyme Q10’s efficacy in mitigating organ dysfunction. Her academic influence extends through her roles as a physician and educator, mentoring emerging researchers in pharmacology. Dr. Bulut’s dedication to drug safety and therapeutic research has not only bolstered her professional reputation but also holds promise for improving patient care and drug efficacy in clinical settings.

Professional Profile

Education

Dr. Seval Bulut’s educational background exemplifies her dedication to the fields of medicine and pharmacology. She earned her MD from Atatürk University Faculty of Medicine in 2001, embarking on her journey as a physician committed to improving patient outcomes. Dr. Bulut later transitioned to academia, pursuing a doctoral program at Erzincan Binali Yıldırım University’s Institute of Health Sciences, Department of Medical Pharmacology. In 2024, she completed her PhD with a thesis titled “The Effect of Liv-52 on Favipiravir-Induced Hepatotoxicity in Rats: Biochemical and Histopathological Evaluation,” demonstrating her keen focus on pharmacology, particularly in drug-induced toxicity. This advanced education has equipped Dr. Bulut with a strong foundation in both clinical and research aspects of pharmacology, enabling her to investigate the biochemical mechanisms of drug interactions and develop therapeutic strategies for organ protection. Her academic journey reflects a consistent focus on integrating medical practice with pharmacological research to address real-world health challenges.

Professional Experience

Dr. Bulut’s professional experience is rooted in her dual roles as a clinician and researcher. She initially practiced medicine across various health institutions from 2001 to 2010, gaining valuable hands-on experience that provided her with a comprehensive understanding of patient care. Transitioning to a Family Physician role between 2010 and 2024, she developed a strong patient-focused perspective, which later became integral to her research approach. Currently, Dr. Bulut serves as an Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University. In this academic role, she has combined her clinical insights with research expertise, conducting studies on pharmacological interventions to protect against drug-induced organ damage. Her extensive background in clinical medicine complements her current research endeavors, where she investigates the biochemical and histopathological mechanisms of pharmacological agents. This blend of professional experience positions Dr. Bulut as a knowledgeable researcher who brings both theoretical and practical insights to her field.

Research Interests

Dr. Seval Bulut’s research interests lie at the intersection of pharmacology, toxicology, and therapeutic interventions. She is particularly focused on understanding drug-induced toxicity and the protective effects of natural compounds on organ systems. Her work has centered on evaluating the biochemical and histopathological mechanisms of various pharmacological agents, including the impact of drugs such as favipiravir on liver health. Dr. Bulut’s studies also explore natural compounds like coenzyme Q10 and cinnamon extract for their potential to mitigate organ dysfunction, particularly in kidney and liver applications. Additionally, she has examined the effects of pharmaceutical compounds on reproductive health, as well as protective pharmacological strategies for conditions such as ischemic ocular syndrome. Her research contributes to improving drug safety and efficacy, providing insights that could lead to safer clinical applications and therapeutic innovations. Through her interdisciplinary research, Dr. Bulut aims to enhance the understanding of pharmacodynamics and pharmacokinetics in therapeutic contexts.

Research Skills

Dr. Seval Bulut has developed a broad set of research skills essential to her pharmacological studies. She is adept in designing and conducting in vivo experiments, specifically using animal models to assess drug efficacy and toxicity. Her skills in biochemical and histopathological analysis are evidenced in her research on drug-induced organ toxicity, where she utilizes various biochemical markers and staining techniques to evaluate cellular and tissue changes. Dr. Bulut is also proficient in data analysis and interpretation, crucial for her work in pharmacology and toxicology, where she frequently analyzes complex datasets to draw meaningful conclusions about drug interactions and therapeutic effects. Additionally, she is skilled in the ethical and methodological aspects of animal research, ensuring that her studies meet rigorous scientific standards. Her collaborative skills are reflected in her ability to work alongside other professionals, contributing to a multidisciplinary approach in her studies on pharmacological agents and natural compounds.

Awards and Honors

Dr. Seval Bulut’s academic and professional achievements have earned her recognition in the scientific community. Her prolific publication record includes 45 research articles indexed in SSCI and SCIE, which demonstrates her commitment to advancing pharmacological research. These publications span influential journals, highlighting her research’s impact and relevance in the field. Dr. Bulut’s focus on drug safety, natural therapeutics, and organ protection has led to invitations to present her findings at international congresses, further establishing her as a respected voice in pharmacology. Additionally, her progression from a practicing physician to a PhD-holder and Assistant Professor in a highly specialized research area reflects her dedication to both medical practice and academia. Although specific awards are not listed, her consistent scholarly contributions and active research agenda signal her as a promising candidate for future awards recognizing excellence in research and contributions to pharmacology. Her work holds significant implications for clinical safety and therapeutic advancements, which are critical areas of modern medical research.

Conclusion

Dr. Seval Bulut is a strong candidate for the Best Researcher Award due to her significant contributions to pharmacological research and her commitment to addressing drug safety and therapeutic efficacy. Her expertise, publication volume, and applied research focus on organ protection and biochemical evaluation highlight her as an impactful researcher. Continued emphasis on international collaboration, active conference participation, and funding pursuit could further elevate her profile and ensure sustained research advancements.

Publications Top Notes

  1. Title: Effect of ethyl acetate extract from Usnea longissima on chemotherapy-associated multiple organ dysfunction in rats
    Authors: Bingul, E., Bulut, S., Mammadov, R., Suleyman, H., Mendil, A.S.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 181
    Article ID: 117636
  2. Title: The hormonal mechanism of the effects of meperidine, sertraline, tianeptine, and their combinations on reproductive functions in female rats
    Authors: Yilmaz, B.K., Suleyman, Z., Suleyman, B., Coban, T.A., Suleyman, H.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 178
    Article ID: 117160
  3. Title: Lacidipine, thiamine pyrophosphate and their combination on the ocular ischemic syndrome induced by bilateral common carotid artery ligation
    Authors: Cicek, I., Somuncu, A.M., Altuner, D., Tastan, T.B., Suleyman, H.
    Journal: International Journal of Ophthalmology
    Year: 2024
    Volume: 17, Issue 5
    Pages: 815–821
  4. Title: Effects of adenosine triphosphate, Lacidipine, and Benidipine on 5-fluorouracil-induced kidney damage in rats
    Authors: Dagel, T., Altuner, D., Suleyman, B., Gulaboglu, M., Suleyman, H.
    Journal: European Review for Medical and Pharmacological Sciences
    Year: 2024
    Volume: 28, Issue 6
    Pages: 2538–2549
  5. Title: Comparative study of the protective effects of coenzyme Q10 and cinnamon extract on possible kidney damage and dysfunction of amiodarone in rats
    Authors: Ekici, O., Gul, A., Keskin, E., Gunay, M., Suleyman, H.
    Journal: Clinical and Experimental Nephrology
    Year: 2024
  6. Title: Protective effects of thiamine pyrophosphate and cinnamon against oxidative liver damage induced by an isoniazid and rifampicin combination in rats
    Authors: Yeter, B., Mammadov, R., Koc, Z., Gulaboglu, M., Suleyman, H.
    Journal: Investigacion Clinica (Venezuela)
    Year: 2024
    Volume: 65, Issue 3
    Pages: 321–334
  7. Title: Protective effect of cinnamon extract against cobalt-induced multiple organ damage in rats
    Authors: Isik, B., Suleyman, B., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Frontiers in Pharmacology
    Year: 2024
    Volume: 15
    Article ID: 1384181
  8. Title: Role of L-, N- and T-type calcium channels in achieving maximum analgesic and minimum toxic effect of tramadol
    Authors: Yilmaz, M., Suleyman, B., Mammadov, R., Coskun, R., Suleyman, H.
    Journal: Acta Poloniae Pharmaceutica – Drug Research
    Year: 2024
    Volume: 81, Issue 1
    Pages: 135–143
  9. Title: Protective Effect of Ramipril Against Oxidant and Proinflammatory Cytokine Damage Induced by Ischemia-Reperfusion in Ovarian Tissue in Rats
    Authors: Ulug, P., Nayki, U., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Transplantation Proceedings
    Year: 2024
    Volume: 56, Issue 1
    Pages: 215–222
  10. Title: Effect of pycnogenol on ischemia/reperfusion-induced oxidative and inflammatory damage in the ovaries of rats
    Authors: Dinc, K., Kiremitli, S., Suleyman, B., Altuner, D., Suleyman, H.
    Journal: Tropical Journal of Pharmaceutical Research
    Year: 2023
    Volume: 22, Issue 11
    Pages: 2297–2303

 

 

GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Published on by World Science Awards

Prof GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Research Scholar, The University of Jordan, Jordan

Ghadeer A. Suaifan was born in December 1973 and is a Jordanian national. She is fluent in both Arabic and English. Ghadeer holds a PhD and an MPhil in Medicinal Chemistry and Instrumental Analysis from the University of Bath, UK, and a BSc (Honours) in Pharmacy from Petra University, Jordan. She currently serves as a Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan. Her research interests span medicinal chemistry, nanotechnology, and public health, with significant contributions in optimizing antidiabetic candidates, cancer treatments, and developing advanced analytical techniques. Ghadeer has published extensively and holds several patents.

Profile

Education🎓

From 2001 to 2004, Ghadeer A. Suaifan pursued a PhD in Medicinal Chemistry and Instrumental Analysis at the Department of Pharmacy and Pharmacology, University of Bath, UK. Prior to this, she completed an MPhil in Medicinal Chemistry and Instrumental Analysis at the same institution from 2000 to 2001. Ghadeer began her academic journey with a BSc (Honours) in Pharmacy from the College of Pharmacy, Petra University, Amman, Jordan, which she completed between 1991 and 1996. Her foundational education was acquired at Al-Room Al-Catholic School in Zarka, Jordan, where she earned her General Secondary Education Certificate from 1988 to 1991.

Experience 🏢

Prof. Ghadeer Suaifan is a distinguished Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan, where she has been serving since September 2016. In this role, she leads advanced research and teaching, significantly contributing to the academic and research excellence of the institution. Prior to this, she held the position of Associate Professor from September 2012 to September 2016, during which she focused on enhancing the curriculum and advancing research initiatives in medicinal chemistry and pharmaceutical sciences. From 2005 to 2012, Prof. Suaifan worked as an Assistant Professor at the same faculty, delivering undergraduate and postgraduate courses in pharmaceutical sciences and engaging in significant research activities. Additionally, she served as an Assistant Professor at the Faculty of Pharmacy, Philadelphia University, Amman, Jordan, from 2004 to 2005, where she contributed to the development of pharmaceutical education and research. Prof. Suaifan’s extensive experience and dedication have made her a vital asset to the field of pharmaceutical sciences in Jordan.

Research Interests 🔬

Ghadeer’s research encompasses Medicinal Chemistry and Instrumental Analysis, focusing on optimizing new antidiabetic candidates, elucidating molecular structures, and developing advanced prodrug systems for prostate cancer. Her work extends to Nanotechnology, including biological particle detection, miniaturized instrumentation, and medical diagnostics. She also investigates Public Research, evaluating antibiotic use behaviors and the prevalence of Complementary and Alternative Medicine in Jordan.

Special Awards 🏆

Professor Ghadeer Suaifan has been recognized for her outstanding contributions to research and development. She received the prestigious Ibtikar Award from Mewiin, Kuwait, in 2020. Her dedication to scientific research was further acknowledged with the Samia Mango Award from the Hamdi Mango Center for Scientific Research in Amman, Jordan, in 2018. In 2015, she was honored with the Excellent Oral Presenter Award at the International Conference on Pharmaceutical Sciences (ICPS) held in Dubai. Professor Suaifan’s academic achievements were consistently recognized during her time at the Faculty of Pharmacy, Petra University, where she received University Awards for Best Achievement from 1991 to 1996. In addition to her accolades, she has been a Registered Pharmacist with the Jordanian Pharmacists Association in Amman since January 1996, showcasing her longstanding commitment to the pharmaceutical profession and her continuous contributions to the field.

Publications Top Notes 📚

  1. Magnetic beads-based nanozyme for portable colorimetric biosensing of Helicobacter pylori
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M.B., Darwish, R.M., Alaridah, N., Zourob, M.
    • Year: 2024
    • Journal: Biosensors and Bioelectronics: X, Volume 20, Article 100517
  2. Rapid Colorimetric Quantitative Portable Platform for Detection of Brucella melitensis Based on a Fluorescence Resonance Energy Transfer Assay and Nanomagnetic Particles
    • Authors: Alhogail, S., Chinnappan, R., Suaifan, G.A., Jürgen, P., Zourob, M.M.
    • Year: 2024
    • Journal: ACS Omega, Volume 9, Issue 19, Pages 20997–21005
  3. A cross-sectional study on adult lifestyle habits during the COVID-19 pandemic
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Jbara, W.A., Nassar, R.I.
    • Year: 2024
    • Journal: PLoS ONE, Volume 19, Issue 5, Article e0299668
  4. Synthesis, urease inhibitory and anticancer evaluation of glucosamine-sulfonylurea conjugates
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M., Tahboub, D., Gaurav, A., Khan, M.
    • Year: 2024
    • Journal: Medicinal Chemistry Research, Volume 33, Issue 4, Pages 663–676
  5. Glucosamine substituted sulfonylureas: IRS-PI3K-PKC-AKT-GLUT4 insulin signalling pathway intriguing agent
    • Authors: Suaifan, G.A.R.Y., Alkhawaja, B., Shehadeh, M.B., Hor Kuan, C., Okechukwu, P.N.
    • Year: 2024
    • Journal: RSC Medicinal Chemistry, Volume 15, Issue 2, Pages 695–703
  6. Development of Rapid Aptamer-Based Screening Assay for the Detection of Covid-19 Variants
    • Authors: Aloraij, Y.M., Suaifan, G.A.R.Y., Shibl, A., Al-Kattan, K., Zourob, M.M.
    • Year: 2023
    • Journal: ACS Omega, Volume 8, Issue 36, Pages 32877–32883
  7. Medicinal plants of Jordan: Scoping review
    • Authors: Abu-Odeh, A., Fino, L., Al-Absi, G., Shehadeh, M., Suaifan, G.
    • Year: 2023
    • Journal: Heliyon, Volume 9, Issue 6, Article e17081
  8. Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy
    • Authors: Suaifan, G.A.R.Y., Abdel Rahman, D.M.A., Abu-Odeh, A.M., Shehadeh, M.B., Darwish, R.M.
    • Year: 2023
    • Journal: PLoS ONE, Volume 18, Issue 3, Article e0282705
  9. Knowledge, practice and attitude associated with SARS-CoV-2 Delta Variant among adults in Jordan
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Shahwan, M., Jbara, F.A.
    • Year: 2022
    • Journal: PLoS ONE, Volume 17, Issue 12, Article e0278243